Stock repurchase program, authorized amount (up to) Stock Repurchase Program, Authorized Amount Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Legal Proceedings Legal Matters and Contingencies [Text Block] Changes in operating assets and liabilities which provided (used) cash: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] U.S. Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Class of Treasury Stock Class of Treasury Stock [Table Text Block] Work-in-process Inventory, Work in Process, Gross Earnings Per Share Earnings Per Share, Policy [Policy Text Block] State Current State and Local Tax Expense (Benefit) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net (loss) income Net (loss) income Net Income (Loss) Attributable to Parent Convertible promissory note, net Total in Other Current Assets, beginning balance Total in Other Current Assets, ending balance Debt Securities, Available-for-sale, Current Net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] 2023 Contractual Obligation, to be Paid, Year Two Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Security Exchange Name Security Exchange Name Combioxin Combioxin [Member] Combioxin Provisions / Adjustments Sales Revenue Allowance, Provisions And Adjustments Sales Revenue Allowance, Provisions And Adjustments Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Other assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Vasopressin Milestone Vasopressin Milestone [Member] Vasopressin Milestone Expected volatility Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 2023 Long-Term Debt, Maturity, Year Two Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Installment sale - Malta Deferred Tax Liabilities, Intangible Assets Convertible Promissory Note Activity Debt Securities, Available-for-sale [Table Text Block] Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization expense of intangible assets Amortization of Intangible Assets Net deferred tax assets Deferred Tax Assets, Net Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Anti-dilutive common shares equivalents outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] Prepaid income taxes Prepaid Taxes Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Cash proceeds from license agreement Proceeds from License Fees Received Award Type [Domain] Award Type [Domain] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] 2024 Long-Term Debt, Maturity, Year Three Beginning balance Ending balance Sales Revenue, Allowance Sales Revenue, Allowance Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Percentage of concentration Concentration Risk, Percentage Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of December 31, 2021 and 2020 Preferred Stock, Value, Issued Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Accretion of discount on convertible promissory note Accretion Income Accretion Income Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Retained Earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Advertising and Marketing Advertising Cost [Policy Text Block] Advertising and marketing costs Marketing and Advertising Expense Lease liability Deferred Tax Liabilities, Leasing Arrangements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Related Party [Axis] Related Party [Axis] Accelerated share repurchases, shares received (in shares) Accelerated Share Repurchases, Shares Received Accelerated Share Repurchases, Shares Received Accounts receivable Increase (Decrease) in Accounts Receivable Right-of-use asset obtained in exchange for lease obligation, inclusive of a lease amendment Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Award vesting percentage of target number granted Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Prime Rate Prime Rate [Member] Basic (in dollars per share) Earnings Per Share, Basic Total intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Intrinsic Value 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Purchase of equity investment security Payments to Acquire Equity Securities, FV-NI 2022 2022 Long-Term Debt, Maturity, Year One Unamortized debt issuance expense Unamortized Debt Issuance Expense Schedule of Product Information [Table] Schedule of Product Information [Table] Balance Sheet Classification as of December 31, 2021 Balance Sheet Classification [Abstract] Balance Sheet Classification Raw materials Inventory, Raw Materials, Gross Sales Revenue, Deductions [Roll Forward] Sales Revenue, Deductions [Roll Forward] Sales Revenue, Deductions 2024 Purchase Obligation, to be Paid, Year Three Diluted net (loss) income per share Earnings Per Share, Diluted [Abstract] Accrued research & development Accrued Research and Development, Current Accrued Research and Development, Current Weighted Average Grant Date Fair Value (Per Share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Payment of employee withholding tax upon vesting of stock-based awards Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Operating cash flows for operating leases Operating Lease, Payments 2025 Contractual Obligation, to be Paid, Year Four Research and Development Expense Research and Development Expense, Policy [Policy Text Block] Convertible Promissory Note, net, beginning balance Convertible Promissory Note, net, ending balance Receivables, Net, Current Entity Voluntary Filers Entity Voluntary Filers Assets: Assets, Fair Value Disclosure [Abstract] Total Long-term Debt Total financial assets Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill impairment Goodwill, Impairment Loss Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] October 2018 Plan October 2018 Plan [Member] October 2018 Plan [Member] Entity Small Business Entity Small Business Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Product Returns Product Returns [Member] Product Returns Interest Income Interest Income, Debt Securities, Available-for-sale, Operating Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders' equity Liabilities and Equity Employee-related expenses Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent All other Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Pending Litigation Pending Litigation [Member] AOP Orphan Pharmaceuticals GmbH AOP Orphan Pharmaceuticals GmbH [Member] AOP Orphan Pharmaceuticals GmbH Milestone Performance-Based Stock Units Milestone Performance-Based Stock Units [Member] Milestone Performance-Based Stock Units Commitments Commitments Disclosure [Text Block] Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Medicaid Rebates Medicaid Rebate [Member] Medicaid Rebate Additional paid in capital Additional Paid in Capital Concentration Risk [Line Items] Concentration Risk [Line Items] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Organization and Business Business Description and Basis of Presentation [Text Block] Accumulated Impairment Charges Finite-Lived Intangible Assets, Impairment Finite-Lived Intangible Assets, Impairment Common stock repurchases Cash paid for repurchases of common stock Treasury Stock, Value, Acquired, Cost Method Operating expenses: Operating Expenses [Abstract] Block trade closing price (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Entity Interactive Data Current Entity Interactive Data Current 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Issuance of common stock upon exercise of stock option grants Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Fair value adjustments on settled accelerated share repurchase agreement Fair Value Adjustment On Accelerated Share Repurchases Fair Value Adjustment On Accelerated Share Repurchases 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Selling, general and administrative Selling, General and Administrative Expense Forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Other comprehensive loss, net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Total deferred tax assets Deferred Tax Assets, Gross Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province Deferred tax asset, net Deferred Income Tax Assets, Net Current liabilities: Liabilities, Current [Abstract] 2025 Long-Term Debt, Maturity, Year Four Debt Debt Disclosure [Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Schedule of Components of Income Tax Provision Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Line of Credit Line of Credit [Member] Common Stock and Stock-Based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Fixed assets Deferred Tax Liabilities, Fixed Assets Deferred Tax Liabilities, Fixed Assets Inventories Inventory Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Total Contractual Obligation Weighted average contractual terms of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Number of reportable segments Number of Reportable Segments Accrued professional fees Accrued Professional Fees, Current Accretion of Discount Investment Income, Amortization of Discount Audit Information [Abstract] Audit Information [Abstract] Number of patents, claims dismissed Loss Contingency, Patents Found Not Infringed, Number Federal Current Federal Tax Expense (Benefit) Present value of lease liabilities Total lease liabilities Total lease liabilities Operating Lease, Liability Revenue from External Customers by Products and Services Revenue from External Customers by Products and Services [Table Text Block] Document Transition Report Document Transition Report Prepaid FDA user fee and advances to CROs Prepaid FDA User Fee And Advances To Clinical Research Organizations Prepaid FDA User Fee And Advances To Clinical Research Organizations Common stock, $0.001 par value; 50,000,000 shares authorized; 16,903,034 and 16,739,203 shares issued as of December 31, 2021 and 2020, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total other (expense) income, net Nonoperating Income (Expense) Unrecognized compensation cost expense term Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Upfront payment Collaborative Arrangement, Rights And Obligations, Upfront Payment Collaborative Arrangement, Rights And Obligations, Upfront Payment Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] PSU Performance Shares [Member] Commitments and contingencies Commitments and Contingencies Credit facility Long-term Debt, Fiscal Year Maturity [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Fair Value, by Balance Sheet Grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Payment of debt financing costs Payments of Debt Issuance Costs ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Proceeds from existing revolving credit facility Proceeds from Issuance of Debt Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Convertible Promissory Note Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Auditor Name Auditor Name Cover page. Cover [Abstract] Dilutive effect of stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Total operating expenses Costs and Expenses Summary of Sales Allowances and Related Accruals Schedule Of Sales Revenue, Allowance [Table Text Block] Schedule Of Sales Revenue, Allowance Cost of royalty revenue Royalty Expense Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Treasury stock, shares (in shares) Treasury Stock, Shares Total obligations Contractual Obligation, Fiscal Year Maturity [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Prepaid expenses and other current assets Total Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Second Amended and Restated Credit Agreement Second Amended And Restated Credit Agreement [Member] Second Amended And Restated Credit Agreement [Member] Financial Instrument [Axis] Financial Instrument [Axis] Selling, general and administrative Selling, General and Administrative Expenses [Member] Short-term Debt [Line Items] Short-term Debt [Line Items] Accrued expenses and other liabilities Total Accrued expenses and other liabilities Accrued Liabilities, Current Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Stock based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost 2023 Purchase Obligation, to be Paid, Year Two Office equipment Office Equipment [Member] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Options Share-based Payment Arrangement, Option [Member] Tax effect on stock option exercises, net of forfeitures Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit Effective Income Tax Rate Reconciliation, Stock Options Exercised, Tax Benefit Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] R&D tax credits and Orphan Drug credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Common Stock Common stock Common Stock [Member] Interest income Investment Income, Interest Variable Rate [Axis] Variable Rate [Axis] Ryanodex intangible Royalty Buy-Back Agreement [Member] Royalty Buy-Back Agreement [Member] Income from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Current portion of lease liability Current lease liabilities (included with Accrued expenses and other liabilities) Operating Lease, Liability, Current 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Teva Pharmaceuticals Teva Pharmaceuticals [Member] Teva Pharmaceuticals [Member] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Treasury Stock Treasury Stock [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Convertible promissory note related credit losses Estimated Credit Loss Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal) Interest Receivable, beginning balance Interest Receivable, ending balance Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss Income taxes, net Income Taxes Paid Number of milestones Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Required To Be Met Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Required To Be Met Proceeds from line of credit Proceeds from Lines of Credit Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Other Product [Member] Other Product [Member] Other (expense) income Other Nonoperating Income (Expense) Discount on the note, beginning balance Discount on the note, ending balance Receivable with Imputed Interest, Discount Prepaid insurance Prepaid Insurance Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Royalty payments if product is approved, percentage of net sales Royalty Revenue, Percentage of Net Sales Royalty Revenue, Percentage of Net Sales Total liabilities Liabilities Intangible Assets, Amortization Period Intangible Assets, Amortization Period [Member] S&P Biotechnology S&P Biotechnology [Member] S&P Biotechnology Deferred tax assets Deferred Tax Assets, Net [Abstract] Schedule of Accrued Expenses and Other Liabilities Schedule of Accrued Liabilities [Table Text Block] 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate pre-tax intrinsic value of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Revenue by Major Customers by Reporting Segments Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Common stock, shares, issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code All other Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Purchase obligations Purchase Obligation, Fiscal Year Maturity [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Intangible Assets, Net Intangible Assets Disclosure [Text Block] Repurchases of common stock Cash paid for repurchases of common stock Repurchases of common stock Payments for Repurchase of Common Stock Estimated Useful Life (years) Property, Plant and Equipment, Useful Life Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Amendment Credit Agreement Amendment Credit Agreement [Member] Amendment Credit Agreement [Member] Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Par Pharmaceutical, Inc. et al. v. Eagle Pharmaceuticals, Inc. (Vasopressin) Par Pharmaceutical, Inc. Et Al. V. Eagle Pharmaceuticals, Inc. (Vasopressin) [Member] Par Pharmaceutical, Inc. Et Al. V. Eagle Pharmaceuticals, Inc. (Vasopressin) Long-term lease liabilities (included with Other long-term liabilities) Operating Lease, Liability, Noncurrent Total Current Income Tax Expense (Benefit) Interest expense Interest Expense Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Retained earnings Retained Earnings (Accumulated Deficit) Right-of-use liability Deferred Tax Assets, Operating Lease, Right-of-Use Liability Deferred Tax Assets, Operating Lease, Right-of-Use Liability Lessee, operating lease, term of contract Lessee, Operating Lease, Term of Contract Litigation Case [Domain] Litigation Case [Domain] Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Restricted stock units RSU Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Co-promotion agreement, percentage of net revenue receivable due to collaborator Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Due To Collaborator Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Due To Collaborator Total deferred tax liabilities Deferred Tax Liabilities, Gross Lessee, operating lease, remaining lease term Lessee, Operating Lease, Remaining Lease Term March 2020 Plan March 2020 Plan [Member] March 2020 Plan [Member] Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share Repurchase Program [Axis] Share Repurchase Program [Axis] Income Statement [Abstract] Income Statement [Abstract] Concentration Risk [Table] Concentration Risk [Table] Schedule of Change in Accounting Estimate [Table] Schedule of Change in Accounting Estimate [Table] Maximum aggregate milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Schedule of Phantom Share Unit Activity Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Change in Accounting Estimate [Line Items] Change in Accounting Estimate [Line Items] Repayment of existing revolving credit facility Repayments of Lines of Credit Proceeds from common stock option exercises Proceeds from Stock Options Exercised Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Current Assets, Total Increase (Decrease) in Prepaid Expense and Other Current Assets, Total Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax provision Provision for income taxes Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Inventories Deferred Tax Assets, Inventory Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total Lessee, Operating Lease, Liability, to be Paid Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Accounts Receivable Accounts Receivable [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Expired (in shares) Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Inventories Inventories Inventory, Net Investment in Tyme Other Assets, Fair Value Disclosure Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] 2025 Purchase Obligation, to be Paid, Year Four Federal Deferred Federal Income Tax Expense (Benefit) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Number of milestones required to be met Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Milestones Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Short-term debt Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Net Revenues Revenue Benchmark [Member] Cash paid during the period for: Cash Paid During the Period [Abstract] Cash Paid During the Period [Abstract] Weighted-average grant-date fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Prepaid expenses Deferred Tax Liabilities, Prepaid Expenses Issuance of common stock related to vesting of restricted stock (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued product sales reserves Accrued Product Sales Reserves, Current Accrued Product Sales Reserves, Current Fair Value Adjustment to Embedded Derivative Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Belrapzo Big Bag (or Belrapzo) [Member] Big Bag (or Belrapzo) [Member] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Limitation on executive compensation Effective Income Tax Rate Reconciliation, Limitation On Executive Compensation, Percent Effective Income Tax Rate Reconciliation, Limitation On Executive Compensation, Percent Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Reporting term for partners' net product sales, royalty revenue Royalty Revenue, Commercial Partners' Obligation of Sales Report, Term Royalty Revenue, Commercial Partners' Obligation of Sales Report, Term Issuance of common stock related to vesting of restricted stock Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Debt securities, available-for-sale Debt Securities, Available-for-sale Schedule of Share-based Compensation Cost Share-based Payment Arrangement, Cost by Plan [Table Text Block] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] 2022 Contractual Obligation, to be Paid, Year One (Loss) income before income tax provision Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair value of the note, beginning balance Fair value of the note, ending balance Notes Receivable, Fair Value Disclosure Level 2 Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Valuation allowance Deferred Tax Assets, Valuation Allowance Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Auditor Location Auditor Location Fair value adjustments related to derivative instrument Derivative, Gain (Loss) on Derivative, Net Useful Life (In Years) Finite-Lived Intangible Asset, Useful Life Customer [Axis] Customer [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Document Annual Report Document Annual Report Total other comprehensive loss Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Co-promotion agreement, right to repurchase, amount Securities Purchase Agreement, Co-promotion Agreement, Right To Repurchase, Amount Securities Purchase Agreement, Co-promotion Agreement, Right To Repurchase, Amount Title of 12(b) Security Title of 12(b) Security Total assets Assets Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward] Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward] Deferred income taxes Deferred Income Taxes and Tax Credits Director Director [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration of Major Customers and Vendors Major Customers, Policy [Policy Text Block] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Numerator for diluted earnings per share-net income Net Income (Loss) Available to Common Stockholders, Diluted Numerator Net Income (Loss) Attributable to Parent [Abstract] Numerator for basic earnings per share-net income Net Income (Loss) Available to Common Stockholders, Basic Document Type Document Type Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Accelerated Share Repurchase Accelerated Share Repurchase [Member] Accelerated Share Repurchase [Member] Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Bendeka Bendeka [Member] Bendeka [Member] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Lessee, operating lease, renewal term (up to) Lessee, Operating Lease, Renewal Term Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Litigation Status [Axis] Litigation Status [Axis] Tyme Tyme [Member] Tyme [Member] 2024 Contractual Obligation, to be Paid, Year Three Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Lease Related Disclosures Lease, Cost [Table Text Block] Basic net (loss) income per share Earnings Per Share, Basic [Abstract] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Basic (in shares) Basic weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Noncash operating lease expense related to right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Product sales, net Product [Member] Schedule of Commitments Contractual Obligation, Fiscal Year Maturity [Table Text Block] Accelerated share repurchases, authorized amount Accelerated Share Repurchases, Authorized Amount Accelerated Share Repurchases, Authorized Amount Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Fair value adjustments on equity investment Gain (loss) on fair value adjustments Unrealized Gain (Loss) on Investments Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Treasury stock, at cost, 4,111,622 and 3,682,176 shares as of December 31, 2021 and 2020, respectively Treasury Stock, Value Denominator Weighted Average Number of Shares Outstanding, Diluted [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Share-based payment award, award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Furniture and fixtures Furniture and Equipment [Member] Furniture and Equipment [Member] Schedule of Restricted Stock Unit Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Charges processed / Payments Sales Revenue Allowance, Credits And Payments Sales Revenue Allowance, Credits And Payments Convertible promissory note Receivables, Fair Value Disclosure Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation expense Depreciation, Depletion and Amortization Royalty revenue, percent of net sales threshold Royalty Revenue, Percent Of Net Sales Threshold Royalty Revenue, Percent Of Net Sales Threshold Accelerated share repurchases, initial price paid per share (in dollars per share) Accelerated Share Repurchases, Initial Price Paid Per Share Accrued salary and other compensation Accrued Salaries, Current 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Developed technology Developed Technology [Member] Developed Technology [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Royalties payable to commercial partners Accrued Royalties, Current Financial Instruments [Domain] Financial Instruments [Domain] Other Other Customers [Member] Other Customers [Member] Chargebacks Chargebacks [Member] Chargebacks Cost of product sales Cost of Goods and Services Sold Revenue: Revenues [Abstract] Deferred tax liabilities Deferred Tax Liabilities, Net [Abstract] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Document Period End Date Document Period End Date Purchase of convertible promissory note Payments to Acquire Intangible Assets Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Unrealized loss for convertible promissory note Fair Value Adjustments to the note OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] State income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State Deferred State and Local Income Tax Expense (Benefit) Total lease cost Lease, Cost Property and Equipment Property, Plant and Equipment [Table Text Block] R&D tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Research Credit agreement, term Debt Instrument, Term Income Statement Location [Domain] Income Statement Location [Domain] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Share-based payment award, number of additional shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Expected achievement rate Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Expected Achievement Rate Share-Based Compensation Arrangement By Share-based Payment Award, Fair Value Assumptions, Expected Achievement Rate Advances to commercial manufacturers Advances to commercial manufactures Advances to commercial manufactures Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Other long-term liabilities Other Liabilities, Noncurrent Embedded derivative asset in convertible promissory note Embedded Derivative, beginning balance Embedded Derivative, ending balance Embedded Derivative, Fair Value of Embedded Derivative Asset Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Commercial Rebates Commercial Rebates [Member] Commercial Rebates Shares of common stock repurchased (in shares) Treasury Stock, Shares, Acquired Payment of debt Repayments of Long-term Debt Trading Symbol Trading Symbol (Loss) Earnings per common share: Earnings Per Share [Abstract] Property and equipment Property, Plant and Equipment, Gross Equipment Equipment [Member] Ryanodex Ryanodex [Member] Ryanodex [Member] Cephalon, Inc. Cephalon, Inc. [Member] Cephalon, Inc. [Member] Finished goods Inventory, Finished Goods, Gross Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Long-term debt Long-term Debt, Excluding Current Maturities Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Share-based compensation expense Share-based Payment Arrangement, Expense Convertible Promissory Note Convertible Debt Securities [Member] Entity Current Reporting Status Entity Current Reporting Status Volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Effective tax rate Effective Income Tax Rate Reconciliation, Percent Wholesaler Fees and Other Incentives Wholesaler Fees And Other Incentives [Member] Wholesaler Fees And Other Incentives Amortization of debt issuance costs Amortization of Debt Issuance Costs Accelerated share repurchases, payment Accelerated Share Repurchases, Settlement (Payment) or Receipt Counterparty Name [Axis] Counterparty Name [Axis] Vasopressin Vasopressin [Member] Vasopressin Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Product Information [Line Items] Product Information [Line Items] Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Estimated Credit Loss, beginning balance Estimated Credit Loss, ending balance Debt Securities, Available-for-sale, Allowance for Credit Loss Co-promotion agreement, percentage of promotional sales effort responsible for Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Promotional Sales Effort Responsible For Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Promotional Sales Effort Responsible For Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Co-promotion agreement, percentage of net revenue receivable Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Securities Purchase Agreement, Co-promotion Agreement, Percentage Of Net Revenue Receivable Number of shares available for grant (in shares) Common Stock, Capital Shares Reserved for Future Issuance Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Issuance of common stock upon exercise of stock option grants (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 2022 Purchase Obligation, to be Paid, Year One Diluted (in shares) Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Income Taxes Income Tax Disclosure [Text Block] Related Party [Domain] Related Party [Domain] Interest rate margin Debt Instrument, Basis Spread on Variable Rate Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other asset - equity investment with readily determined fair value Deferred Tax Assets, Investments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Auditor Firm ID Auditor Firm ID Exercisable options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Total Purchase Obligation Credit Facility [Axis] Credit Facility [Axis] New York Federal Reserve Bank (NYFRB) New York Federal Reserve Bank (NYFRB) [Member] New York Federal Reserve Bank (NYFRB) [Member] Number of products launched Number Of Products Launched Number Of Products Launched Royalty revenue Royalty [Member] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Entity Address, Address Line Two Entity Address, Address Line Two Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Non- Exercisable options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Non-exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Non-exercisable, Number Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Entity Shell Company Entity Shell Company Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Payment of employee withholding tax upon vesting of stock-based awards Payment, Tax Withholding, Share-based Payment Arrangement Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Litigation Status [Domain] Litigation Status [Domain] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loss Contingencies [Table] Loss Contingencies [Table] Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] All other Other Assets, Current Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other Other assets Increase (Decrease) in Other Noncurrent Assets Statistical Measurement [Axis] Statistical Measurement [Axis] Number of Restricted Stock Units Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures [Abstract] Deferred tax assets, operating loss carryforwards, foreign Deferred Tax Assets, Operating Loss Carryforwards, Foreign Net Book Value Intangible assets Finite-Lived Intangible Assets, Net Goodwill Goodwill Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent License and other revenue License [Member] Inventories Inventory, Policy [Policy Text Block] Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Marketing exclusivity term Marketing Exclusivity Term Marketing Exclusivity Term Operating lease cost Operating lease rent expense Operating Lease, Cost Related Party Transactions Related Party Transactions Disclosure [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Total Deferred Income Tax Expense (Benefit)